153 related articles for article (PubMed ID: 29575713)
1. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
Martínez-Canales S; López de Rodas M; Nuncia-Cantarero M; Páez R; Amir E; Győrffy B; Pandiella A; Galán-Moya EM; Ocaña A
Cancer Med; 2018 May; 7(5):1896-1907. PubMed ID: 29575713
[TBL] [Abstract][Full Text] [Related]
2. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
3. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
Li J; Zhi X; Shen X; Chen C; Yuan L; Dong X; Zhu C; Yao L; Chen M
Biochem Biophys Res Commun; 2020 Mar; 523(2):434-440. PubMed ID: 31875843
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target.
Huang GZ; Chen ZQ; Wu J; Shao TR; Zou C; Ai YL; Lv XZ
J Immunol Res; 2021; 2021():9250207. PubMed ID: 34950739
[TBL] [Abstract][Full Text] [Related]
5. UBE2C promotes the progression of head and neck squamous cell carcinoma.
Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Machino H; Honjoh H; Kawata Y; Kashiyama T; Asada K; Tanikawa M; Mori-Uchino M; Tsuruga T; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
BMC Cancer; 2019 May; 19(1):455. PubMed ID: 31092221
[TBL] [Abstract][Full Text] [Related]
7. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
8. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.
Li R; Pang XF; Huang ZG; Yang LH; Peng ZG; Ma J; He RQ
BMC Cancer; 2021 Sep; 21(1):996. PubMed ID: 34488675
[TBL] [Abstract][Full Text] [Related]
9. UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.
Palumbo A; Da Costa NM; De Martino M; Sepe R; Pellecchia S; de Sousa VP; Nicolau Neto P; Kruel CD; Bergman A; Nasciutti LE; Fusco A; Pinto LF
Oncotarget; 2016 Oct; 7(40):65876-65887. PubMed ID: 27588470
[TBL] [Abstract][Full Text] [Related]
10. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Jones BA; Varambally S; Arend RC
Mol Cancer Ther; 2018 Mar; 17(3):591-602. PubMed ID: 29726819
[TBL] [Abstract][Full Text] [Related]
11. Combined elevation of AURKB and UBE2C predicts severe outcomes and therapy resistance in glioma.
Alafate W; Zuo J; Deng Z; Guo X; Wu W; Zhang W; Xie W; Wang M; Wang J
Pathol Res Pract; 2019 Oct; 215(10):152557. PubMed ID: 31353228
[TBL] [Abstract][Full Text] [Related]
12. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
13. In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.
Khedkar HN; Wang YC; Yadav VK; Srivastava P; Lawal B; Mokgautsi N; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072728
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
Yang X; Wang J; Li H; Sun Y; Tong X
Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
[TBL] [Abstract][Full Text] [Related]
15. The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance.
Gong Y; Wang D; Lin L; Dai J; Yu L
Medicine (Baltimore); 2019 Nov; 98(46):e17896. PubMed ID: 31725636
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.
Xie C; Powell C; Yao M; Wu J; Dong Q
Int J Biochem Cell Biol; 2014 Feb; 47():113-7. PubMed ID: 24361302
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of cell division cycle-associated protein 7 (CDCA7) suppresses cell proliferation, arrests cell cycle of ovarian cancer, and restrains angiogenesis by modulating enhancer of zeste homolog 2 (EZH2) expression.
Cai C; Peng X; Zhang Y
Bioengineered; 2021 Dec; 12(1):7007-7019. PubMed ID: 34551671
[TBL] [Abstract][Full Text] [Related]
18. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker.
Hao Z; Zhang H; Cowell J
Tumour Biol; 2012 Jun; 33(3):723-30. PubMed ID: 22170434
[TBL] [Abstract][Full Text] [Related]
20. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
